Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$68.14 USD

68.14
3,235,540

+2.46 (3.75%)

Updated Oct 4, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

5 Best Stocks From 100 Days of Coronavirus

by Tirthankar Chakraborty

Here're five big stock winners from the first 100 days of the coronavirus pandemic that ravaged the global economy and shook the stock market.

The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Reckitt Benckiser, Henkel AG, DexCom, Tencent and Peloton Interactive

Trina Mukherjee headshot

3 MedTech Stocks to Watch Amid Coronavirus Catastrophe

by Trina Mukherjee

Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $393, moving -1.44% from the previous trading session.

Urmimala Biswas headshot

Economic Recovery Debate Heats Up: 4 Sectors Holding Ground

by Urmimala Biswas

Here we discuss four sectors for which COVID-19 has opened up enormous growth prospects.

Sriparna Ghosal headshot

3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

by Sriparna Ghosal

Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments

DexCom (DXCM) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $385.17, marking a +1.23% move from the previous day.

DexCom's (DXCM) G6 CGM System Gets CE Marking in Europe

by Zacks Equity Research

DexCom (DXCM) announces the receipt of CE Marking across Europe for its G6 CGM System.

ABIOMED Gets FDA Nod for First-in-Human Trial of Impella ECP

by Zacks Equity Research

This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product line.

Here's Why You Should Retain AmerisourceBergen Stock Now

by Zacks Equity Research

Investor confidence is high on AmerisourceBergen (ABC) stock, thanks to solid prospects.

Here's Why You Should Retain Ecolab in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Ecolab (ECL) stock, thanks to solid prospects.

Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for JKH

ABIOMED's (ABMD) Impella RP Receives FDA's EUA Clearance

by Zacks Equity Research

This regulatory approval is expected to boost ABIOMED's (ABMD) Impella product portfolio.

Sanghamitra Saha headshot

Do You Always Look for Earnings Beat? 5 Sectors to Play

by Sanghamitra Saha

These sectors came up with stellar earnings beat in the recent cycle. Investors can play the associated stocks that delivered an earnings surprise.

Here's Why You Should Add Accuray to Your Portfolio Now

by Zacks Equity Research

Investor confidence is high on Accuray (ARAY) stock, thanks to solid prospects.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

by Zacks Equity Research

DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.

DexCom (DXCM) Up 4.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Inogen in Your Portfolio Now

by Zacks Equity Research

Investor confidence is high in Inogen (INGN) stock, thanks to solid prospects.

Varian (VAR) Unveils New Features for Noona Software

by Zacks Equity Research

This development, which is in response to the challenges brought on by the pandemic, is expected to boost Varian's (VAR) Oncology segment.

Sreoshi Bera headshot

5 Health Care Stocks to Bet on as Coronavirus Woes Linger

by Sreoshi Bera

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

Sanghamitra Saha headshot

S&P 500 Touches 3,000 Again: Winning Stocks of IVV ETF

by Sanghamitra Saha

The S&P 500 has rallied 1.2% on May 26, topping the 3,000-mark for the first time since Mar 5.

    Here's Why You Should Add Surmodics to Your Portfolio Now

    by Zacks Equity Research

    Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.

    Here's Why You Should Retain Merit Medical (MMSI) for Now

    by Zacks Equity Research

    Investor confidence is high in Merit Medical (MMSI) stock, thanks to solid prospects.

    Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform

    by Zacks Equity Research

    This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.

      Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

      by Zacks Equity Research

      Is (DXCM) Outperforming Other Medical Stocks This Year?